Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New weapon may help flush stealth stashes of HIV in cells

29.09.2003


Researchers find positive results in people with HIV



The evolving science of "flushing" hidden reservoirs of HIV from cells got a encouraging boost today as researchers at Georgetown University Medical Center demonstrated how an experimental intranasal drug can activate the immune system and send HIV viral counts in white blood cells to undetectable levels.

Published in the latest issue of Peptides, this is the first human study to assess antiviral and immune effects of the experimental therapy, called Peptide T®. Although a small trial, it yielded statistically significant data on Peptide T’s ability to purify cells housing hidden HIV virus without any harmful side effects. This flushing mechanism gives promise to a new class of viral entry inhibitor drugs as a complement or perhaps even an alternative to the popular but costlier and complicated "highly active anti-retroviral therapies" (HAART) drug regimens.


"Every person in the study took Peptide T, and in each one of them, we observed quite a remarkable phenomenon – their white blood cell reservoirs of virus plummeted, some to undetectable levels," said Candace Pert, PhD, professor of physiology, co-discoverer of Peptide T, and lead Georgetown investigator of this study. "We’ve come a long way and undoubtedly have a ways to go, but the way Peptide T stirred the immune system and flushed the HIV cellular reservoirs is very encouraging to me."

Conceptually, Peptide T could play a valuable role in the fight against HIV. While current anti-retroviral drug cocktails successfully kill active, replicating HIV, the virus also has a frustrating ability to hide silently in cells for an indeterminate time period. A formidable foe, these hidden sources of virus may instantly be triggered and cause the virus to suddenly and aggressively kick start, beginning the chain of events that leads to the progression toward HIV/AIDS.

People with HIV currently remain on HAART drugs long after their virus plasma levels dip to undetectable levels simply because doctors know that hidden stores of virus hide within cells, looking for an opportunistic gateway to open and allow them to act up. If Peptide T one day conclusively flushes these hidden viral components out of the system for good, HIV-positive people could cease taking the costly drug cocktails they currently take as a defensive measure.

"Is flushing the viral reservoirs an actual clinical benefit? Can you actually get HIV-positive people off of HAART drugs as a result of taking Peptide T?," posed Michael Ruff, PhD, professor of physiology at Georgetown, co-discoverer of Peptide T and senior author of the study. "We simply do not know yet based on this data. However, there is enough evidence of clinical activity here to push Peptide T research to the next level to see if it really can serve as a valuable weapon against stealth stashes of virus."

Based out of St. Francis Hospital in San Francisco, 11 HIV-positive men were enrolled in the trial. All participants were classified as long-term non-progressors, meaning they had lived many years without their HIV developing into full blown AIDS. All participants also had low levels of viremia present in their systems upon entering the trial. Some had never been on HAART therapy, while others took HAART and Peptide T simultaneously during the 32 week-long trial.

At the conclusion, overall viral plasma levels had not changed, but all 11 men experienced profound reductions of HIV in the cellular reservoir.

Additionally, five out of 11 had a mean CD4 increase of 33 percent, a telltale sign of positive immune response in people with HIV, and each of these five responders showed an added immune response in the form of an increase in antiviral T cells that fight against HIV. The people who fared best took HAART and Peptide T simultaneously.

"There is a great deal of excitement about CCR5 entry inhibitors, and Peptide T may well be a novel one in the treatment of HIV," said Frank Ruscetti, prominent virologist and co-author of this study. "It is very clear that it served as an effective inhibitor of viral infections. I’d now like to see broader, placebo-controlled trials with a much more diverse patient base. Ideally we’d enroll people who have just been diagnosed with HIV, are HAART naïve, and some with much higher viral loads than those tested in this trial."

Drs. Pert and Ruff discovered Peptide T -- a synthetic compound of amino acids -- while Pert was serving as the chief of the brain biochemistry section at the National Institute of Mental Health in the late 1980s. It works by blocking HIV from entering cells by binding to the CCR5 receptors the virus uses to enter and infect cells. This is a much different action that antivirals that work directly on HIV or infected cells.

Earlier studies conducted on Peptide T sponsored by the National Institutes of Health have reported neurocognitive and brain imaging benefits of Peptide T in people with AIDS. Importantly, all previous studies have demonstrated that there are no toxicities associated with Peptide T.


The U.S Government holds the patent on Peptide T, as Dr. Pert discovered it while working for the NIH. Advanced Immunity, Inc. licensed Peptide T.

The Institute for New Medicine is a not-for-profit foundation founded by Drs. Pert and Ruff. Expert on Peptides, Inc. supports Drs. Pert and Ruff through support of their Georgetown salaries.

Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through our partnership with MedStar Health). Our mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis--or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, and the world renowned Lombardi Cancer Center.

Lindsey Spindle | EurekAlert!
Further information:
http://gumc.georgetown.edu/

More articles from Health and Medicine:

nachricht Custom-tailored strategy against glioblastomas
26.09.2016 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New welding process joins dissimilar sheets better

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of light metals.
Scientists at the University of Stuttgart have now developed two new process variants that will considerably expand the areas of application for friction stir welding.
Technologie-Lizenz-Büro (TLB) GmbH supports the University of Stuttgart in patenting and marketing its innovations.

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of...

Im Focus: First quantum photonic circuit with electrically driven light source

Optical quantum computers can revolutionize computer technology. A team of researchers led by scientists from Münster University and KIT now succeeded in putting a quantum optical experimental set-up onto a chip. In doing so, they have met one of the requirements for making it possible to use photonic circuits for optical quantum computers.

Optical quantum computers are what people are pinning their hopes on for tomorrow’s computer technology – whether for tap-proof data encryption, ultrafast...

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

Im Focus: Complex hardmetal tools out of the 3D printer

For the first time, Fraunhofer IKTS shows additively manufactured hardmetal tools at WorldPM 2016 in Hamburg. Mechanical, chemical as well as a high heat resistance and extreme hardness are required from tools that are used in mechanical and automotive engineering or in plastics and building materials industry. Researchers at the Fraunhofer Institute for Ceramic Technologies and Systems IKTS in Dresden managed the production of complex hardmetal tools via 3D printing in a quality that are in no way inferior to conventionally produced high-performance tools.

Fraunhofer IKTS counts decades of proven expertise in the development of hardmetals. To date, reliable cutting, drilling, pressing and stamping tools made of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

European Health Forum Gastein 2016 kicks off today

28.09.2016 | Event News

Laser use for neurosurgery and biofabrication - LaserForum 2016 focuses on medical technology

27.09.2016 | Event News

Experts from industry and academia discuss the future mobile telecommunications standard 5G

23.09.2016 | Event News

 
Latest News

A perfect sun-storm

28.09.2016 | Earth Sciences

New welding process joins dissimilar sheets better

28.09.2016 | Power and Electrical Engineering

European Health Forum Gastein 2016 kicks off today

28.09.2016 | Event News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>